Alkem Laboratories Ltd (ALKEM) — shareholding pattern, promoter holding, financials and share price
About Alkem Laboratories Ltd (ALKEM)
Alkem Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ALKEM and on the BSE under scrip code 539523. Its ISIN is INE540L01014.
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
Alkem Laboratories Limited is a Mumbai-headquartered integrated pharmaceutical company that develops, manufactures and sells branded generics, generic formulations, APIs, biosimilars and nutraceuticals in India and internationally, supported by 18 manufacturing facilities, R&D centres and a growing subsidiary ecosystem (Enzene, Alkem MedTech, Ascend, Pharmacor and others).
Q3 FY26 results showed resilient performance: consolidated revenue of ₹37,368 million (+10.7% YoY), EBITDA ₹8,280 million at a 22.2% margin and PAT of ₹6,360 million, while international businesses grew 26.6% YoY led by the US and non‑US markets, signalling successful portfolio and geographic execution.
Listed peers in Pharmaceuticals: Aurobindo Pharma Ltd, Laurus Labs Ltd, Biocon Ltd, Glenmark Pharmaceuticals Ltd, Abbott India Ltd, Ipca Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹5,675 a share on 10 Jul 2026, Alkem Laboratories Ltd (ALKEM) was valued at a price-to-earnings ratio of 28.84x against an industry P/E of 36.41x and a price-to-book of 5.66x on a book value of ₹1,002.37 per share as of Mar 2025. Solomo computes return on equity of 19.63% and return on capital employed of 22.68% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 28.84x
- Industry P/E
- 36.41x
- P/B
- 5.66x
- EPS (TTM)
- ₹196.81
- Book value / share
- ₹1,002.37
- ROE
- 19.63%
- ROCE
- 22.68%
- ROA
- 13.3%
- Debt / equity
- 0.12x
- Dividend yield
- 0.9%
- EBITDA margin
- 23.2%
- 52-week range
- ₹4,740.6 – ₹5,933
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Alkem Laboratories Ltd (ALKEM) reported revenue of ₹14,712 crore, net profit of ₹2,351 crore and earnings per share of ₹192.51. That compares with revenue of ₹12,965 crore and net profit of ₹2,215 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹3,603 crore and net profit ₹251 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 10,634 | 11,599 | 12,668 | 12,965 | 14,712 |
| Net profit (₹ cr) | 1,680 | 1,007 | 1,811 | 2,215 | 2,351 |
| EPS (₹) | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 9.32% | 5.71% | -0.06% | 2.34% |
| Profit growth | 12.92% | 10.57% | 10.68% | 22.33% |
| Stock price CAGR | 15% | 11% | 16% | 14% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 49.7% of Alkem Laboratories Ltd (ALKEM) (down 1.5 pp QoQ), foreign institutional investors (FII) hold 10.42% and domestic institutional investors (DII) hold 22.63%. Market capitalisation was ₹67,853 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2015.
Largest disclosed public shareholders in Jun 2026: Hdfc Mutual Fund - Hdfc Mid-Cap Fund 4.77%, Icici Prudential Multi-Asset Fund 3.57%, Kishor Kumar Singh 2.49%, Alok Kumar 2.31%, Ashok Kumar 2.25%, Deepak Kumar Singh 2.01%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 49.7% | - | 10.42% | 22.63% | 50.3% |
| Mar 2026 | 51.2% | - | 10.16% | 21.4% | 48.8% |
| Dec 2025 | 51.2% | - | 9.97% | 21.54% | 48.8% |
| Sep 2025 | 51.2% | - | 9.48% | 21.93% | 48.8% |
| Jun 2025 | 53.04% | - | 9.11% | 21.8% | 46.96% |
| Mar 2025 | 55.13% | - | 9.41% | 19.42% | 44.87% |
| Dec 2024 | 55.66% | - | 10.15% | 18.01% | 44.34% |
| Sep 2024 | 55.66% | - | 9.02% | 19.21% | 44.34% |